TSLP Inhibitors Market
Nov 17, 2025
TSLP Inhibitors: The New Frontier in Treating Type 2 Inflammatory Diseases
Thymic stromal lymphopoietin (TSLP) has emerged as a key target in the treatment of severe inflammatory diseases. These TSLP therapies offer a novel approach by targeting a key initiator of the inflammatory cascade. Following AstraZeneca and Amgen’s TEZSPIRE’s breakthrough approvals and a robust pipeline of emergin...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
